Your browser doesn't support javascript.
loading
Circulation of Type 2 Vaccine-Derived Poliovirus in China in 2018-2019.
Zhao, Hehe; Ma, Xiaozhen; Tang, Haishu; Zhang, Yong; Chen, Na; Kaisaier, Wusiman; Wang, Qi; Wang, Cheng; Zhu, Shuangli; Qi, Qi; Liu, Yu; Ma, Qianli; Yang, Qing; Li, Junhan; Wang, Dongyan; Li, Xiaolei; Xiao, Jinbo; Zhu, Hui; Xu, Wenbo; Tong, Wenbin; Yan, Dongmei.
Afiliação
  • Zhao H; WHO WPRO Regional Polio Reference Laboratory, NHC Key Laboratory of Biosafety and NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.
  • Ma X; Sichuan Center for Disease Control and Prevention, Chengdu, People's Republic of China.
  • Tang H; Xinjiang Uygur Autonomous Region Center for Disease Control and Prevention, Urumqi, People's Republic of China.
  • Zhang Y; WHO WPRO Regional Polio Reference Laboratory, NHC Key Laboratory of Biosafety and NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.
  • Chen N; Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People's Republic of China.
  • Kaisaier W; Sichuan Center for Disease Control and Prevention, Chengdu, People's Republic of China.
  • Wang Q; Xinjiang Uygur Autonomous Region Center for Disease Control and Prevention, Urumqi, People's Republic of China.
  • Wang C; Xinjiang Uygur Autonomous Region Center for Disease Control and Prevention, Urumqi, People's Republic of China.
  • Zhu S; Sichuan Center for Disease Control and Prevention, Chengdu, People's Republic of China.
  • Qi Q; WHO WPRO Regional Polio Reference Laboratory, NHC Key Laboratory of Biosafety and NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.
  • Liu Y; Sichuan Center for Disease Control and Prevention, Chengdu, People's Republic of China.
  • Ma Q; Sichuan Center for Disease Control and Prevention, Chengdu, People's Republic of China.
  • Yang Q; Sichuan Center for Disease Control and Prevention, Chengdu, People's Republic of China.
  • Li J; Sichuan Center for Disease Control and Prevention, Chengdu, People's Republic of China.
  • Wang D; WHO WPRO Regional Polio Reference Laboratory, NHC Key Laboratory of Biosafety and NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.
  • Li X; WHO WPRO Regional Polio Reference Laboratory, NHC Key Laboratory of Biosafety and NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.
  • Xiao J; WHO WPRO Regional Polio Reference Laboratory, NHC Key Laboratory of Biosafety and NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.
  • Zhu H; WHO WPRO Regional Polio Reference Laboratory, NHC Key Laboratory of Biosafety and NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.
  • Xu W; WHO WPRO Regional Polio Reference Laboratory, NHC Key Laboratory of Biosafety and NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.
  • Tong W; WHO WPRO Regional Polio Reference Laboratory, NHC Key Laboratory of Biosafety and NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.
  • Yan D; Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People's Republic of China.
Open Forum Infect Dis ; 8(12): ofab535, 2021 Dec.
Article em En | MEDLINE | ID: mdl-34926714
ABSTRACT

BACKGROUND:

China implemented the globally synchronized switch from trivalent oral poliovirus vaccine (tOPV) to bivalent OPV (bOPV) on May 1, 2016. During April 2018 to May 2019, the first outbreak caused by type 2 circulating vaccine-derived poliovirus (cVDPV2) after the switch occurred in Xinjiang and Sichuan, China. Methods. We performed sequence analysis of VP1 and the whole genome to determine the genomic characteristics of type 2 cVDPVs, and carried out coverage surveys to assess the risk of viral propagation. Surveillance for environment and acute flaccid paralysis was intensified to enhance case ascertainment. Results. Comparison of the complete genomes between early (Xinjiang strain) and late strains (Sichuan strains) revealed that recombination pattern and reverse mutation of attenuation sites had been fixed early, but the mutations of the neutralizing antigenic sites were introduced over the circulation. The Markov Chain Monte Carlo tree showed that the cVDPV2 initial infection was April 2016, earlier than the switch. So, we speculated that the cVDPV2 was originated from tOPV recipients and spread among children with a low level of immunity against the type 2.

CONCLUSIONS:

The detection of this outbreak combined acute flaccid paralysis (AFP) surveillance with environmental surveillance (ES) indicates that ES should be expanded geographically to further complement AFP surveillance.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Open Forum Infect Dis Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Open Forum Infect Dis Ano de publicação: 2021 Tipo de documento: Article